HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Delavirdine (Rescriptor)

Subscribe to New Research on Delavirdine

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

Also Known As:

Rescriptor; Delavirdine Mesylate; Pfizer Brand of Delavirdine Mesilate; U-90152; U-90152S; Mesylate, Delavirdine; U 90152; U 90152S; U90152; U90152S; Piperazine, 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)-

Networked: 42 relevant articles (0 outcomes, 9 trials/studies)

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Piperazines: 18
    - Delavirdine: 42
- 2-Ring Heterocyclic Compounds
  - Indoles: 95
    - Delavirdine: 42

Experts

1.	De Clercq, Erik: 3 articles (09/2009 - 11/2002)
2.	De Clercq, E: 3 articles (01/2007 - 08/2001)
3.	Morse, Gene D: 3 articles (01/2005 - 01/2003)
4.	Freimuth, William W: 2 articles (01/2003 - 01/2003)
5.	Della-Coletta, Andrew A: 2 articles (01/2003 - 01/2003)
6.	Shelton, Mark J: 2 articles (01/2003 - 01/2003)
7.	Acosta, E P: 2 articles (05/2001 - 07/2000)
8.	Harrer, Thomas: 1 article (01/2015)
9.	Hecht, Markus: 1 article (01/2015)
10.	Fietkau, Rainer: 1 article (01/2015)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2005 - "Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies. " 04/05/2002 - "Delavirdine is a newly developed anti-HIV-1 drug for AIDS therapy. " 07/01/1997 - "Delavirdine mesylate (U-90152T) is a highly specific nonnucleoside HIV-1 reverse transcriptase inhibitor currently under development for the treatment of AIDS. " 07/01/1997 - "Delavirdine mesylate (U-90152T) is a highly specific nonnucleoside HIV-1 reverse transcriptase inhibitor currently under development for the treatment of AIDS. " 02/01/1997 - "Delavirdine mesylate (U-90152T) is a highly specific nonnucleoside reverse transcriptase inhibitor currently under development for the treatment of AIDS. "
2.	HIV Infections (HIV Infection) 01/01/2003 - "Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection." 12/01/2000 - "Delavirdine: a review of its use in HIV infection." 01/01/2009 - "To the best of our knowledge, the indole derivatives have been considered as one class of promising HIV-1 inhibitors, such as delavirdine approved by the Food and Drug Administration (FDA) in 1997 for use in combination with other antiretrovirals in adults with HIV infection. " 12/01/2000 - "Delavirdine is an effective component of recommended antiretroviral treatment strategies for adult patients with HIV infection and, in combination with 2 NRTIs as a first-line therapy, the drug has the advantage of sparing protease inhibitors for subsequent use. " 12/01/2000 - "delavirdine produces sustained improvements in surrogate markers of HIV disease and prolongs the time to virological failure in adult patients with HIV infection. "
3.	Exanthema (Rash) 12/01/2000 - "Skin rash is the most frequently reported adverse effect, occurring in 18 to 50% of patients receiving delavirdine-containing combination therapy in clinical trials. " 06/01/2000 - "The incidence of rash is rather similar under these two compounds, but severe rash is less frequent with delavirdine. " 08/01/1999 - "Gastrointestinal side effects were experienced by 33% of patients (178 of 544), and 30% (121 of 407) receiving delavirdine experienced rash, only one case of which was severe. " 06/01/1999 - "Rash, which was usually self-limited, developed in 36% of subjects who received delavirdine. " 07/01/2000 - "While rash due to delavirdine occurred more often, the rash due to nevirapine was more severe and resulted in hospitalization more frequently. "
4.	Disease Progression 12/01/1996 - "The trials used as background evidence showed no significant difference between combinations with and without delavirdine, and no less disease progression was seen. "
5.	Bacteremia 12/01/1996 - "Also included are data tables showing the impact of viral load and CD4 count on risk of progression among 2,008 persons in trials of delavirdine; the detection of HIV RNA after 40 to 52 weeks in a trial of nevirapine/ZDV/ddI; viral load and CD4 changes in a phase I/II study of 141W94; viral load changes, principal side effects, and dropouts in a trial of ritonavir plus saquinavir; clinical endpoint results of the CAESAR trial; viral load and CD4 changes after 50 weeks of IL-2 plus indinavir; comparison of regimens for treating CMV retinitis; prevalence of Kaposi's sarcoma-associated herpesvirus antigen in HIV-positive and -negative groups; and rates of MAC bacteremia in ACTG 196/CPCRA 009, a trial comparing clarithromycin, rifabutin, and the combination for prophylaxis."

Related Drugs and Biologics

1.	Indinavir (Crixivan)
2.	Ritonavir (Norvir)
3.	Saquinavir (Invirase)
4.	Zidovudine (Retrovir)
5.	Nelfinavir (Viracept)
6.	Nevirapine (Viramune)
7.	Lamivudine (3TC)
8.	Stavudine (Zerit)
9.	efavirenz (Sustiva)
10.	amprenavir (141W94)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)